An observational study in Coronary Artery Disease, Acute Coronary Syndrome and Stable Angina, sponsored by University of Pennsylvania. Terminated. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-06-11.
Sponsored by University of Pennsylvania · Observational
To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.
A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans
B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's enrollment of 51 is below the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.
Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients scheduled to have PTCA
Patients with existing CAD admitted for elective PTCA:
Exclusion Criteria:
Drug: No ASA
Drug: Low dose ASA
Drug: 325 mg ASA
Alternative antiplatelet therapy instead of aspirin
Low dose aspirin (81mg) prior to PTCA
high dose of aspirin prior to PTCA
The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite.
Time frame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.
Whether aspirin could blunt the increment of PGD2 if there is.
Time frame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.
No study locations are listed for this record.
This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pennsylvania